Ultragenyx Pharmaceutical (RARE) Competitors $37.98 +0.47 (+1.24%) As of 10:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RARE vs. SMMT, RDY, ASND, MRNA, VTRS, QGEN, BPMC, ROIV, RVMD, and VRNAShould you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry. Ultragenyx Pharmaceutical vs. Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Blueprint Medicines Roivant Sciences Revolution Medicines Verona Pharma Summit Therapeutics (NASDAQ:SMMT) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, community ranking, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment. Does the MarketBeat Community believe in SMMT or RARE? Ultragenyx Pharmaceutical received 526 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 77.56% of users gave Ultragenyx Pharmaceutical an outperform vote while only 58.47% of users gave Summit Therapeutics an outperform vote. CompanyUnderperformOutperformSummit TherapeuticsOutperform Votes31458.47% Underperform Votes22341.53% Ultragenyx PharmaceuticalOutperform Votes84077.56% Underperform Votes24322.44% Which has more volatility & risk, SMMT or RARE? Summit Therapeutics has a beta of -1.06, meaning that its stock price is 206% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Is SMMT or RARE more profitable? Summit Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -101.60%. Summit Therapeutics' return on equity of -85.42% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -85.42% -52.66% Ultragenyx Pharmaceutical -101.60%-193.80%-38.15% Do institutionals & insiders hold more shares of SMMT or RARE? 4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 84.9% of Summit Therapeutics shares are owned by insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts prefer SMMT or RARE? Summit Therapeutics presently has a consensus target price of $35.09, suggesting a potential upside of 60.81%. Ultragenyx Pharmaceutical has a consensus target price of $88.77, suggesting a potential upside of 133.76%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92 Does the media refer more to SMMT or RARE? In the previous week, Summit Therapeutics had 8 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 16 mentions for Summit Therapeutics and 8 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.95 beat Summit Therapeutics' score of 0.53 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, SMMT or RARE? Ultragenyx Pharmaceutical has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K23,151.02-$614.93M-$0.34-64.18Ultragenyx Pharmaceutical$590.69M6.08-$569.18M-$5.88-6.46 SummaryUltragenyx Pharmaceutical beats Summit Therapeutics on 12 of the 19 factors compared between the two stocks. Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RARE vs. The Competition Export to ExcelMetricUltragenyx PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.59B$6.85B$5.60B$8.67BDividend YieldN/A2.49%5.27%4.19%P/E Ratio-5.998.8227.3320.12Price / Sales6.08263.82417.24161.29Price / CashN/A65.8538.2534.64Price / Book13.766.657.124.72Net Income-$569.18M$143.49M$3.23B$247.80M7 Day Performance3.73%4.70%3.59%2.77%1 Month Performance8.01%15.02%13.12%9.75%1 Year Performance-8.27%5.96%32.28%15.01% Ultragenyx Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAREUltragenyx Pharmaceutical3.9689 of 5 stars$37.98+1.2%$88.77+133.8%-10.6%$3.59B$590.69M-5.991,310Positive NewsAnalyst RevisionSMMTSummit Therapeutics2.9993 of 5 stars$17.73-2.7%$37.40+110.9%+176.7%$13.17B$700,000.00-63.32110Analyst ForecastAnalyst RevisionGap UpHigh Trading VolumeRDYDr. Reddy's Laboratories1.1953 of 5 stars$14.73+0.0%$17.00+15.4%+9.5%$12.29B$325.54B23.4524,800ASNDAscendis Pharma A/S3.2589 of 5 stars$175.69+7.9%$216.07+23.0%+31.1%$10.71B$368.70M-24.75640Positive NewsAnalyst ForecastAnalyst RevisionMRNAModerna4.418 of 5 stars$27.05+1.8%$53.58+98.1%-81.4%$10.46B$3.14B-2.913,900Trending NewsVTRSViatris2.1627 of 5 stars$8.69-1.1%$10.50+20.8%-14.0%$10.20B$14.33B-11.7437,000QGENQiagen3.1324 of 5 stars$44.89-0.5%$48.42+7.9%+6.0%$9.98B$2.00B125.006,030BPMCBlueprint Medicines0.8531 of 5 stars$127.79+26.1%$125.69-1.6%+23.0%$8.25B$562.12M-118.32640High Trading VolumeROIVRoivant Sciences2.3295 of 5 stars$11.17+1.6%$17.50+56.7%+7.5%$7.97B$29.05M-74.46860RVMDRevolution Medicines4.1708 of 5 stars$40.65+3.2%$67.08+65.0%+5.3%$7.57B$742,000.00-11.32250VRNAVerona Pharma1.7043 of 5 stars$84.10+3.6%$82.13-2.3%+586.0%$6.82B$118.54M-43.8030Positive NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Summit Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Moderna Alternatives Viatris Alternatives Qiagen Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Verona Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RARE) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RARE Stock Free RARE Stock Alerts